Amarin Corp Plc (AMRN)

[ziploc_1]

It is my hope that the Teva vs.Glaxo trial showcases the 'skinny label'end run around the HW law, which enables infringing generics to get rich by subverting the law's intention to reward innovation, while preserving price stability...and this case stimulates Congress to reexamine HW with a view to amending it to eliminate the 'skinny label' disincentive to companies to invest in innovation, which is so important to finding superior treatments to help patients.